Skip to content
Screener

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$22.32B+28.0%
Gilead Sciences logo
Gilead SciencesGILD
$11.83B-39.9%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
$148.09M-23.4%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$347.5M+133%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$736.05M+5.4%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$278.88M-27.6%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$483.93M+261%
Enterprise value$460.9M+433%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219397
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity
Preferred stock, 10,000,000 shares authorized, $0.00001 par value, no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.00001 par value; 490,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 60,532,500 and 60,389,893 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.11
Additional paid-in capital660,230657,005
Accumulated other comprehensive income/(loss)(96)97
Accumulated deficit(464,555)(424,827)
Total stockholders’ equity195,580232,276
Total liabilities and stockholders’ equity$257,024$293,826

Item 1. Financial Statements (unaudited)

FAQ

What is Kyverna Therapeutics, Inc.'s total equity?
Kyverna Therapeutics, Inc. (KYTX) reported total equity of $195.58M in Q1 2026.
How has Kyverna Therapeutics, Inc.'s total equity changed year-over-year?
Kyverna Therapeutics, Inc.'s total equity decreased by 12.7% year-over-year, from $224.01M to $195.58M.
What is the long-term trend for Kyverna Therapeutics, Inc.'s total equity?
Over 3 years (2022 to 2025), Kyverna Therapeutics, Inc.'s total equity has grown at a 46.4% compound annual growth rate (CAGR), from -$74M to $232.28M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Kyverna Therapeutics, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude